Recce clears key regulatory hurdle in Indonesia as Phase 3 trial advances toward approval

April 21, 2026 News

This is a preview of subscriber content

Subscribe now to continue reading.

The trial, known as R327 G301, is progressing across five sites in Indonesia, with patient dosing ongoing and an interim analysis planned once 155 patients have been completed. …

Subscribe now to continue reading.

Latest Video

New Stories

Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News

Recce clears key regulatory hurdle in Indonesia as Phase 3 trial advances toward approval

This is a preview of subscriber content

Latest Video

Most Read

Officials talk down the prospect of MFN impact on the PBS

An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'

Invitation confusion clouds Delphi studies and captures medical device sector

Officials confirm shift in Budget management of underspends

A clear disconnect between the public and private on 'Most Favored Nation' pricing

New Stories

Opthea returns to ASX and works to restart eye therapy candidate

A clear disconnect between the public and private on 'Most Favored Nation' pricing

New blueprint charts a potential policy path forward on biosimilars

Officials cite company consultation, system changes, and spending approvals to justify delay

Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science

Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception

Officials talk down the prospect of MFN impact on the PBS

Sign In

Recce clears key regulatory hurdle in Indonesia as Phase 3 trial advances toward approval

This is a preview of subscriber content

Latest Video

Most Read

Officials talk down the prospect of MFN impact on the PBS

An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'

Invitation confusion clouds Delphi studies and captures medical device sector

Officials confirm shift in Budget management of underspends

A clear disconnect between the public and private on 'Most Favored Nation' pricing

Follow Us

New Stories

Opthea returns to ASX and works to restart eye therapy candidate

A clear disconnect between the public and private on 'Most Favored Nation' pricing

New blueprint charts a potential policy path forward on biosimilars

Officials cite company consultation, system changes, and spending approvals to justify delay

Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science

Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception

Officials talk down the prospect of MFN impact on the PBS